Did You Miss it?
Did you miss this compelling article published in the December issue? Non-melanoma skin cancers, like squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), are a significant concern in dermatology. But could a common diabetes medication like metformin offer protection?
A recent study dives into this intriguing possibility, using the extensive All of Us research database to explore how metformin might reduce the risk of these cancers. The findings? Metformin exposure appears linked to a lower risk of SCC and BCC across many groups, with particularly promising results for patients with skin of color.
While the data is compelling, there’s more to uncover about how metformin fits into skin cancer prevention. Dive into the full article to explore the study’s insights, methods, and what this could mean for your patients.
